Galapagos NV (ADR)  

(Public, NASDAQ:GLPG)   Watch this stock  
Find more results for PINK:GLPYY
62.91
+0.71 (1.14%)
Aug 4 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 62.75 - 63.64
52 week 12.91 - 63.64
Open 63.53
Vol / Avg. 31,898.00/37,098.00
Mkt cap 2.42B
P/E     -
Div/yield     -
EPS     -
Shares 37.42M
Beta 0.76
Inst. own     -
Sep 23, 2015
Galapagos NV at Petercam Benelux Conference Add to calendar
Sep 16, 2015
Galapagos NV at Morgan Stanley Healthcare Conference Add to calendar
Sep 11, 2015
Galapagos NV at Goldman Sachs European Medtech and Healthcare Services Conference Add to calendar
Aug 7, 2015
Half Year 2015 Galapagos NV Earnings Release - 1:30AM EDT - Add to calendar
Jul 30, 2015
Galapagos NV Selective JAK1 Inhibitor Filgotinib Meets Key Efficacy Endpoints Call
Jun 15, 2015
Galapagos NV at Citi European Healthcare Conference
More events from DailyFinance »    

Address

Industriepark Mechelen Noord Generaal De Wittelaan L11 A3
MALINES (MECHELEN), 2800
Belgium
+32-15-342900 (Phone)
+32-15-342901 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Galapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.

Officers and directors

Onno van de Stolpe Chief Executive Officer, Executive Director
Age: 56
Bio & Compensation  - Reuters
Bart Filius Chief Financial Officer
Bio & Compensation  - Reuters
Andre Hoekema Senior Vice President - Corporate Development
Bio & Compensation  - Reuters
Piet Wigerinck Chief Scientific Officer
Bio & Compensation  - Reuters
Rajesh Parekh Non-Executive Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
Harrold van Barlingen Non-Executive Director
Age: 50
Bio & Compensation  - Reuters
Katrine Bosley Independent Non-Executive Director
Bio & Compensation  - Reuters
Werner Cautreels Non-Executive Independent Director
Age: 63
Bio & Compensation  - Reuters
Howard Rowe Non-Executive Independent Director
Bio & Compensation  - Reuters